Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the “real world”
- 21 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Annals of Hematology
- Vol. 100 (5), 1261-1266
- https://doi.org/10.1007/s00277-021-04420-3
Abstract
Carfilzomib, a next-generation proteasome inhibitor, improves outcomes in patients with multiple myeloma (MM); however, a proportion of those treated develop renal failure due to adverse event, comorbidity, or myeloma progression. The rate of renal failure and associated risk factors remains unknown in real-world populations. Adults with relapsed/refractory MM who received carfilzomib between the years 2013 and 2016 were identified in the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked databases. Renal failure was defined using the corresponding International Classification of Diseases, Ninth Revision (ICD-9) and Tenth Revision (ICD-10) diagnostic codes and procedure codes for dialysis. Patients with a pre-existing diagnosis of renal failure were excluded to distinguish an adverse event from comorbidity. Multivariate cox regression analysis was performed to identify the variables independently associated with the development of renal failure among MM patients utilizing carfilzomib. A total of 1950 patients were included in the analysis. Renal failure developed in 22% of patients during the study period. The median time to development of renal failure from first carfilzomib administration was 1.6 months (range < 0.1–23.3). Increasing age (adjusted hazard ratio [aHR] 1.01 per year, p = 0.018), pre-existing heart failure (aHR 1.50, p = 0.005), and pre-existing chronic kidney disease (aHR 2.00, p < 0.001) were associated with a higher risk of developing renal failure. Renal failure occurred in up to 22% of patients on carfilzomib therapy. The exact cause and mechanism of renal failure cannot be determined from our study and may be multifactorial. Future studies are needed to further understand the cause of renal failure among patients on carfilzomib and devise strategies to mitigate the risk.Keywords
Funding Information
- National Center for Advancing Translational Sciences (UL1 TR002345)
- Agency for Healthcare Research and Quality (R24 HS19455)
This publication has 25 references indexed in Scilit:
- Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?Blood Cancer Journal, 2016
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre studyThe Lancet Oncology, 2015
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple MyelomaThe New England Journal of Medicine, 2015
- Multiple Myeloma in the Older Adult: Better Prospects, More ChallengesJournal of Clinical Oncology, 2014
- Carfilzomib-Associated Tumor Lysis SyndromePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2014
- Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trialsHaematologica, 2013
- Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safetyLeukemia, 2013
- Carfilzomib-related acute kidney injury.2013
- Validity of International Classification of Diseases, Ninth Revision, Clinical Modification Codes for Acute Renal FailureJournal of the American Society of Nephrology, 2006
- Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.Published by Rockefeller University Press ,2002